The impact of additive or substitutive clinical study design on the negotiated reimbursement for oncology pharmaceuticals after early benefit assessment in Germany

Abstract Background We analysed the impact of clinical study design for oncological pharmaceuticals on the subsequent price negotiations after early benefit assessment between pharmaceutical companies and the German National Association of Statutory Health Insurance Funds. The analysis was conducted...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Hoofdauteurs: C. M. Dintsios, I. Beinhauer
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: BMC 2020-03-01
Reeks:Health Economics Review
Onderwerpen:
Study design
Negotiated prices
Oncological drugs
Pharmaceutical companies
Payers
German statutory health insurance
Online toegang:http://link.springer.com/article/10.1186/s13561-020-00263-2
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items